<antigenSupportingData>
<immunity>
</immunity>
<contraindications>
<vaccineGroup>
<contraindication>
<observationCode>080</observationCode>
<observationTitle>Adverse reaction to vaccine component</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had an adverse reaction to a vaccine component.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>270</observationCode>
<observationTitle>Severe allergic reaction after previous dose of Chikungunya vaccine</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had a severe allergic reaction after a previous dose of Chikungunya vaccine.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
</vaccineGroup>
</contraindications>
<series>
<seriesName>Chikungunya Risk 1-dose series</seriesName>
<targetDisease>Chikungunya</targetDisease>
<vaccineGroup>Chikungunya</vaccineGroup>
<seriesAdminGuidance>On 8/22/2025 the US FDA's Center for Biologics Evaluation and Research (CBER) has suspended the biologics license for Valneva Austria GmbH's live-attenuated IXCHIQ vaccine. CBER's decision is based on serious safety concerns related to the vaccine, which appears to be causing chikungunya-like illness in vaccine recipients. There has been one death from encephalitis directly attributable to the vaccine.</seriesAdminGuidance>
<seriesAdminGuidance>In general, vaccination of pregnant women should be deferred until after delivery. However, when the risk of infection is high (e.g., during an outbreak) and exposure cannot be avoided, a healthcare provider and pregnant woman should discuss the risks of chikungunya virus infection and the potential benefits and risks of vaccination</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups/>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>1</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>1</seriesPreference>
<minAgeToStart>12 years</minAgeToStart>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Traveling to a country or territory where there is a chikungunya outbreak</text>
<code>271</code>
</observationCode>
<description>Administer to persons traveling to a country or territory where there is a chikungunya outbreak</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance>Areas with a current Chikungunya outbreak: https://www.cdc.gov/chikungunya/data-maps/index.html</guidance>
</indication>
<indication>
<observationCode>
<text>Traveling or moving to a country or territory without an outbreak but with elevated chikungunya risk for U.S. travelers if planning to stay for an extended period of time [e.g., 6 months or more]</text>
<code>272</code>
</observationCode>
<description>Persons traveling or moving to a country or territory without an outbreak but with elevated chikungunya risk for U.S. travelers if planning to stay for an extended period of time [e.g., 6 months or more] may consider vaccination</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance>Areas with an elevated risk for U.S. travelers: https://www.cdc.gov/chikungunya/data-maps/index.html</guidance>
</indication>
<indication>
<observationCode>
<text>Laboratory worker with potential for exposure to chikungunya virus</text>
<code>277</code>
</observationCode>
<description>Administer to laboratory workers with potential for exposure to chikungunya virus</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>12 years - 4 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval/>
<allowableInterval/>
<preferableVaccine>
<vaccineType>Chikungunya, VLP, recombinant, 0.8 mL, PF</vaccineType>
<cvx>329</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.8</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge>18 years - 4 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>Chikungunya, VLP, recombinant, 0.8 mL, PF</vaccineType>
<cvx>329</cvx>
<beginAge>12 years - 4 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
</antigenSupportingData>
